The cure for some chronic injuries can be elusive, with the most challenging aspect being the return to life or sports without chronic pain or a permanent injury. Research in the rapidly expanding field of regenerative medicine has found promising uses for amnion tissue in the form of amnion injections to heal sport’s injuries. Some patients are turning to amniotic membrane injections to regenerate healthy tissue around an injury, rather than letting it heal into problematic scar tissue. Amniotic injections are used for tendon and nerve pain . Achilles, plantar fascia, nerve pain or neuropathy can all benefit from stem cell injections.
Because the literature supporting another regenerative treatment, platelet-rich plasma (PRP) injections, remains controversial, it is especially timely to consider amnion injection as an option. Recently published randomized and case studies reported improvement in new healthy cell growth with amnion injection.
Unlike PRP, amnion does not require the patient’s own blood. And though they both theoretically deliver a “regenerative punch” to the injured tissues by concentrating growth factors calling into action the body’s own adult stem cells to repair the damage, platelet-derived growth factors are less effective because adult stem cells are already significantly differentiated and unable to regrow into the useful, less-differentiated progenitor cell lines. (Progenitor cells are early descendants of embryonic stem cells, and are, in turn, more limited in what they may become than embryonic stem cells.)
Mesenchymal stem cells as progenitor cells
Mesenchymal stem cells (MSCs) are a specific class of tissue-specific stem cells present in the fetus (in the blood, liver, bone marrow and kidneys), and sparsely present in the adult human body (bone marrow, kidneys, lungs and liver). They possess bone- and fat-producing differentiation potentials under appropriate conditions. Research shows that placenta-derived cells have multi-lineage differentiation potential similar to MSCs in terms of morphology, cell-surface antigen expression, and gene expression patterns. The placenta is therefore a useful source of MSCs.
Properly processed, amniotic membrane preserves the complete spectrum of human growth factors. Some products actually contain living mesenchymal stem cells. Amnion injection stimulates tissue remodeling by modulation of tissue colony aggregates that resembles the genesis of embryonic tissue cell lines in the fetus. Amnion cells are also immune-privileged. Therefore, host vs. graft rejection has not been reported.
Tendons and ligaments are some of the strongest connective tissues of the body, and as such, are subject to common overuse injuries from cumulative microtrauma. Tendon cells, or tenocytes, are elongated fibroblast type cells. The cytoplasm is stretched between the collagen fibers of the tendon. They have a central cell nucleus with a prominent nucleolus. Tendon cells have a well-developed rough endoplasmic reticulum and they are responsible for synthesis and turnover of tendon fibers and ground substance. Tendon cells form a connecting layer between the muscle.
Less invasive than surgery with rapid results
Treatment of sports injuries with amniotic membrane injection offers advantages over other invasive or surgical methods. Typically the patient will be evaluated with a thorough physical exam and different imaging modalities that may include radiographs, echo sonogram or musculoskeletal ultrasound, MRI or a combination of these. Once the problem is ascertained, treatment involves rest, ice, compression and elevation (RICE), custom orthoses, bracing, athletic tape strappings and physical therapy adjunctive modalities.
However, when rapid recovery is desired, amniotic injections offer a promising alternative. Several products are available, all of them manufactured from donated placentas delivered from planned cesarean-section births. These are processed under FDA-approved, proprietary-patented processes that consist of antisepsis with minimal tissue manipulation in order to qualify for human tissue implantation.
The office-based injection procedure involves provision of local anesthesia, preparation of the site with aseptic technique, reconstitution of the dry placental particulate or thawing of the pre-filled cryopreserved syringe. The injection is then applied with minimal trauma to the patient and a light sterile bandage is applied. The practitioner may opt to immobilize the extremity for a short period and recommend icing and narcotic analgesics for pain control if necessary. The physician will also withhold post-injection corticosteroids or NSAIDS to avoid disrupting the adult MSCs from cascading to the treatment site, having been activated by the injection of placental growth factors.
The convalescence period is typically short: from three to five days of rest, with gradual return to regular activity at the patient’s own tolerance.